Search Results for "allergy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for allergy. Results 141 to 150 of 193 total matches.

Desk-Top Systems For Office Chemistries

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 1990  (Issue 829)
, Ther Drug Monitoring, 11:73, 1989), theophylline (P Singh, Ann Allergy, 59:176, 1987), triglycerides ...
Four different desk-top systems are now widely used in physicians'; offices to measure blood chemistries. The Ektachem DT (Kodak) and Reflotron (Boehringer Mannheim), reviewed previously in The Medical Letter (volume 30, page 119, 1988; volume 31, page 90, 1989), resemble the Seralyzer (Miles Diagnostics) in cost; the Vision (Abbott), which is fully automated, is much more expensive.
Med Lett Drugs Ther. 1990 Oct 19;32(829):96-8 |  Show IntroductionHide Introduction

Rimantadine for Prevention and Treatment of Influenza

   
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993  (Issue 910)
if influenza vaccine cannot be given because of allergy, if the epidemic strain differs from the antigens ...
Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.
Med Lett Drugs Ther. 1993 Nov 26;35(910):109-10 |  Show IntroductionHide Introduction

Formoterol (Foradil Aerolizer) For Asthma

   
The Medical Letter on Drugs and Therapeutics • May 14, 2001  (Issue 1104)
symptom scores (G Bensch et al, Ann Allergy Asthma Immunol 2001; 86:19). Concurrent use of formoterol ...
Formoterol fumarate inhalation powder Foradil Aerolizer, a long-acting beta2-adrenergic receptor agonist, has been approved by the FDA for maintenance treatment of asthma and prevention of exercise-induced bronchospasm. The drug has been available in Europe for many years.
Med Lett Drugs Ther. 2001 May 14;43(1104):39-40 |  Show IntroductionHide Introduction

Haegarda - A Subcutaneous C1 Esterase Inhibitor for Prevention of Hereditary Angioedema

   
The Medical Letter on Drugs and Therapeutics • Feb 26, 2018  (Issue 1541)
Allergy Organ J 2012; 5:182. 3. BL Zuraw et al. Nanofiltered C1 inhibitor concentrate for treatment ...
The FDA has approved Haegarda (CSL Bering), a human plasma-derived C1 esterase inhibitor (C1INH), for prophylaxis against hereditary angioedema (HAE) attacks in adolescents and adults. Haegarda is the fourth C1INH to be approved by the FDA and the second to be approved for HAE prophylaxis. Unlike the other C1INHs, Haegarda is self-administered subcutaneously rather than intravenously.
Med Lett Drugs Ther. 2018 Feb 26;60(1541):39-40 |  Show IntroductionHide Introduction

Drugs for Pneumonia

   
Treatment Guidelines from The Medical Letter • Sep 01, 2003  (Issue 13)
allergy will also develop allergic reactions to a cephalosporin; no skin testing materials are available ...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
Treat Guidel Med Lett. 2003 Sep;1(13):83-8 |  Show IntroductionHide Introduction

Brimonidine - An Alpha2-Agonist for Glaucoma

   
The Medical Letter on Drugs and Therapeutics • Jun 06, 1997  (Issue 1002)
of ocular allergy. Pilocarpine, the most commonly used cholinergic agent, increases aqueous humor outflow ...
Brimonidine tartrate 0.2% ophthalmic solution (Alphagan - Allergan), a selective alpha2-adrenergic agonist, has been approved by the US Food and Drug Administration (FDA) for treatment of increased intraocular pressure due to open-angle glaucoma or ocular hypertension and for its prevention in patients undergoing argon laser trabeculoplasty.
Med Lett Drugs Ther. 1997 Jun 6;39(1002):54-5 |  Show IntroductionHide Introduction

Budesonide Turbuhaler for Asthma

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 1998  (Issue 1018)
-powder inhaler (S Pedersen and P O’Byrne, Allergy, 52 suppl 39:13, 1997). More comparative trials would ...
The FDA has approved marketing of the corticosteroid budesonide in an oral inhalatoin powder formulation (Pulmicort Turbuhaler - Astra) for maintenance treatment of asthma in adults and children at least six years old. Budesonide has been available in the USA as an intranasal spray (Rhinocort) for treatment of allergic rhinitis since 1994 and has been used for inhalation treatment of asthma in Canada and Europe for ten years.
Med Lett Drugs Ther. 1998 Jan 16;40(1018):15-6 |  Show IntroductionHide Introduction

Echinacea for Prevention and Treatment of Upper Respiratory Infections

   
The Medical Letter on Drugs and Therapeutics • Apr 01, 2002  (Issue 1127)
-documented anaphylaxis has been reported (RJ Mullins and R Heddle, Ann Allergy Asthma Immunol 2002; 88:42 ...
Echinacea, a plant also called purple coneflower, is widely used as a dietary supplement for prevention and treatment of colds.
Med Lett Drugs Ther. 2002 Apr 1;44(1127):29-30 |  Show IntroductionHide Introduction

Tattoo Removal

   
The Medical Letter on Drugs and Therapeutics • Nov 24, 2003  (Issue 1170)
, presumably to the tattoo pigments, have been reported (RW England et al, Ann Allergy Asthma Immunol 2002; 89 ...
While more people than ever are getting tattoos, many come to regret their decision and would like to have them removed. The technology of removing tattoos is much better than it used to be, but still far from perfect. Complete removal of all pigments with restoration of normal skin color and texture is not always possible (M Kuperman-Beade et al, Am J Clin Dermatol 2001; 2:21; GM Lipper and RR Anderson in IM Freedberg et al, eds, Fitzpatrick's Dermatology in General Medicine 6th ed, New York:McGraw-Hill 2003, page 2508).
Med Lett Drugs Ther. 2003 Nov 24;45(1170):95-6 |  Show IntroductionHide Introduction

Reslizumab (Cinqair) for Severe Eosinophilic Asthma

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy ...
The FDA has approved reslizumab (Cinqair – Teva), a humanized interleukin-5 (IL-5) antagonist monoclonal antibody, for add-on maintenance treatment of severe asthma in adults who have an eosinophilic phenotype. It is the second IL-5 antagonist to be approved in the US; mepolizumab (Nucala) was approved for the same indication in 2015.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):81-2 |  Show IntroductionHide Introduction